<DOC>
	<DOCNO>NCT02435992</DOCNO>
	<brief_summary>The purpose study determine whether RPC1063 effective treatment Ulcerative Colitis ( UC ) .</brief_summary>
	<brief_title>Safety Efficacy Trial RPC1063 Moderate Severe Ulcerative Colitis</brief_title>
	<detailed_description>The trial compose 2 period : Induction Maintenance . Patients enter trial 2 separate cohort Induction Period ( 10 week ) patient clinical response end Induction Period proceed Maintenance Period . Participation period 52 week . Patients may also qualify participate optional Open-Label Extension study .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Key Ulcerative Colitis ( UC ) confirm endoscopy Moderately severely active UC ( Mayo score 612 ) Currently receive treatment aminosalisylate , prednisone , budesonide Key Diagnosis Crohn 's disease indeterminate colitis presence history fistula consistent Crohn 's disease microscopic colitis radiation colitis ischemic colitis Clinically relevant cardiovascular condition relevant disease could impact implementation interpretation trial , put patient risk History uveitis macular edema Pregnancy , lactation , positive serum βhuman chorionic gonadotropin ( βhCG ) measure Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>